Clinical Trials Browser

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Adenocarcinoma, Rectal Neoplasms

Colorectal Neoplasms

Breast Neoplasms, Meningeal Neoplasms

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

Colonic Neoplasms

Brain Neoplasms

Breast Neoplasms

Metastatic Breast Cancer With a Isolated Brain Progression

Breast Neoplasms, Meningeal Neoplasms

Breast Neoplasms

Anatomic Stage II Breast Cancer AJCC v8

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

HER2-positive Breast Cancer

Breast Neoplasms

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Breast Neoplasms

Breast Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Brain Neoplasms, Breast Neoplasms, Central Nervous System Diseases

Brain Neoplasms

Breast Neoplasms

Clinical Trials

I-SPY

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

H3RAKLES

TAPUR

ERASE-CRC

Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer

TrasTUCAN

InTTercePT

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

PRE-I-SPY-PI

TUC-TOC

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

TRAIN-4

Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer

Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer

2019-101826

MARGARET

TOPAZ

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)

Tucatinib + Abemaciclib + Herceptin for HER2+ MBC